Recent Advances in Potential Clinical Application of Ghrelin in Obesity
Ghrelin is the natural ligand of the growth hormone secretagogue receptor (GHS-R1a). Ghrelin is a 28 amino acid peptide possessing a unique acylation on the serine in position 3 catalyzed by ghrelin O-acyltransferase (GOAT). Ghrelin stimulates growth hormone secretion, but also appetite, food intake...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Journal of Obesity |
Online Access: | http://dx.doi.org/10.1155/2012/535624 |
id |
doaj-ff4421bff1204212973e2e7be7b99bd2 |
---|---|
record_format |
Article |
spelling |
doaj-ff4421bff1204212973e2e7be7b99bd22020-11-24T21:23:56ZengHindawi LimitedJournal of Obesity2090-07082090-07162012-01-01201210.1155/2012/535624535624Recent Advances in Potential Clinical Application of Ghrelin in ObesityChristine Delporte0Laboratory of Biological Chemistry and Nutrition, Faculty of Medicine, Université libre de Bruxelles, 1070 Brussels, BelgiumGhrelin is the natural ligand of the growth hormone secretagogue receptor (GHS-R1a). Ghrelin is a 28 amino acid peptide possessing a unique acylation on the serine in position 3 catalyzed by ghrelin O-acyltransferase (GOAT). Ghrelin stimulates growth hormone secretion, but also appetite, food intake, weight gain, and gastric emptying. Ghrelin is involved in weight regulation, obesity, type 2 diabetes, and metabolic syndrome. Furthermore, a better understanding of ghrelin biology led to the identification of molecular targets modulating ghrelin levels and/or its biological effects: GOAT, ghrelin, and GHS-R1a. Furthermore, a recent discovery, showing the involvement of bitter taste receptor T2R in ghrelin secretion and/or synthesis and food intake, suggested that T2R could represent an additional interesting molecular target. Several classes of ghrelin-related pharmacological tools for the treatment of obesity have been or could be developed to modulate the identified molecular targets.http://dx.doi.org/10.1155/2012/535624 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christine Delporte |
spellingShingle |
Christine Delporte Recent Advances in Potential Clinical Application of Ghrelin in Obesity Journal of Obesity |
author_facet |
Christine Delporte |
author_sort |
Christine Delporte |
title |
Recent Advances in Potential Clinical Application of Ghrelin in Obesity |
title_short |
Recent Advances in Potential Clinical Application of Ghrelin in Obesity |
title_full |
Recent Advances in Potential Clinical Application of Ghrelin in Obesity |
title_fullStr |
Recent Advances in Potential Clinical Application of Ghrelin in Obesity |
title_full_unstemmed |
Recent Advances in Potential Clinical Application of Ghrelin in Obesity |
title_sort |
recent advances in potential clinical application of ghrelin in obesity |
publisher |
Hindawi Limited |
series |
Journal of Obesity |
issn |
2090-0708 2090-0716 |
publishDate |
2012-01-01 |
description |
Ghrelin is the natural ligand of the growth hormone secretagogue receptor (GHS-R1a). Ghrelin is a 28 amino acid peptide possessing a unique acylation on the serine in position 3 catalyzed by ghrelin O-acyltransferase (GOAT). Ghrelin stimulates growth hormone secretion, but also appetite, food intake, weight gain, and gastric emptying. Ghrelin is involved in weight regulation, obesity, type 2 diabetes, and metabolic syndrome. Furthermore, a better understanding of ghrelin biology led to the identification of molecular targets modulating ghrelin levels and/or its biological effects: GOAT, ghrelin, and GHS-R1a. Furthermore, a recent discovery, showing the involvement of bitter taste receptor T2R in ghrelin secretion and/or synthesis and food intake, suggested that T2R could represent an additional interesting molecular target. Several classes of ghrelin-related pharmacological tools for the treatment of obesity have been or could be developed to modulate the identified molecular targets. |
url |
http://dx.doi.org/10.1155/2012/535624 |
work_keys_str_mv |
AT christinedelporte recentadvancesinpotentialclinicalapplicationofghrelininobesity |
_version_ |
1725990282220011520 |